Table 1. Study characteristics of the 45 eligible articles.
| study | year | country | NO. of samples |
TILs location | tumor stage (I/II/III/IV) |
histologic subtype | biomarkers | outcomes | method | therapy |
|---|---|---|---|---|---|---|---|---|---|---|
| Jeremy Goc[14] | 2014 | America | 376 | TN/TS | I-IV | NSCLC | CD8+ | OS | IHC | surgery |
| Jiewei Chen[15] | 2018 | China | 100 | TN | I-IV | NSCLC | CD8+ | OS/PFS | IHC | surgery |
| Yoichi Ohtaki[16] | 2018 | Japan | 95 | TN/TS | I-IV | NSCLC | CD4+/CD8+/Foxp3+ | OS/RFS | IHC | surgery |
| Chuntao Tian[17] | 2015 | China | 129 | TN | I-III | NSCLC | CD3+/CD8+ | OS | IHC | surgery |
| Zhangguo Hu[18] | 2018 | China | 90 | TN | I-IV | NSCLC | CD8+/CD45+/Foxp3+ | OS/DFS | IHC | surgery |
| Zachary D. Horne, B.S.[28] | 2011 | America | 273 | TN | I | NSCLC | TIL | OS/RFS | IHC | surgery |
| Xiangjiao Meng[29] | 2018 | China | 197 | TN/TS | I-III | NSCLC | CD4+/CD8+/Foxp3+ | OS | IHC | surgery |
| Wen Feng[30] | 2016 | China | 320 | TN | IIIA | NSCLC | TIL | OS | IHC | surgery |
| Tom Donnem[31] | 2015 | Norway | 797 | TS | I-IIIA | NSCLC | CD8+ | OS/DFS/DSS | IHC | surgery |
| TAKEO HASEGAWA[32] | 2014 | Japan | 67 | TN/TS | I-IIIB | NSCLC | CD4+/CD8+/Foxp3+ | OS | IHC | surgery |
| T. Kinoshita[33] | 2016 | Japan | 218 | TN | II-III | NSCLC | CD8+/CD20+/Fxp3+/Treg | OS | IHC | surgery |
| Souptik Barua[34] | 2018 | America | 120 | TN | I-III | NSCLC | CD4+/CD8+/CD68+/Foxp3+ | OS | IHC | surgery |
| Satoshi Ikeda[35] | 2005 | Japan | 83 | TN | I-III | NSCLC | CD8+/TIL | OS | IHC | surgery |
| Rebecca P. Petersen[36] | 2006 | USA | 64 | TN | I | NSCLC | CD3+/Foxp3+ | OS | IHC | surgery |
| Osamu Wakabayashi[37] | 2003 | Japan | 178 | TN/TS | I-IIIA | NSCLC | CD4+/CD8+ | OS | IHC | surgery |
| Mehrdad Talebian Yazdi[38] | 2015 | Netherlands | 197 | TN/TS | I-IV | NSCLC | CD8+/HLA | OS | IHC | surgery |
| Marta Usó[39] | 2016 | Spain | 84 | TN/TS | I-IIIA | NSCLC | CD8+/Foxp3+ | OS/PFS | IHC | surgery |
| Marius Ilie[40] | 2011 | France | 632 | TN | I-III | NSCLC | CD8+ | OS | IHC | surgery |
| Marie-Caroline Dieu-Nosjean[41] | 2008 | France | 74 | TN | I-III | NSCLC | CD3+/CD20+/CD45+ | OS/DSS/DFS | IHC | surgery |
| Kyuichi Kadota[42] | 2015 | America | 331 | TN | I-III | NSCLC | CD3+/CD4+/CD8+/CD20+/Foxp3+ | OS | IHC | surgery |
| Khalid I. Al-Shibli[43] | 2008 | Norway | 335 | TN/TS | I-IIIA | NSCLC | CD4+/CD8+/CD20+ | DSS | IHC | surgery |
| KHALID AL-SHIBLI[44] | 2010 | Norway | 335 | TN/TS | I-IIIA | NSCLC | CD3+/CD117+/CD138+ | DSS | IHC | surgery |
| K Hiraoka[45] | 2006 | Japan | 109 | TS | I-III | NSCLC | CD4+/CD8+ | OS | IHC | surgery |
| Hui Yang[46] | 2018 | China | 178 | TN | I-IV | NSCLC | CD8+ | OS | IHC | surgery |
| Hiroyuki Tao[47] | 2012 | Japan | 87 | TN | I-III | NSCLC | Foxp3+ | OS/RFS | IHC | surgery |
| Haiyue Wang[48] | 2018 | China | 159 | TS | I-III | NSCLC | CD8+ | OS/PFS | IHC | surgery |
| Gian Kayser[49] | 2012 | Germany | 232 | TS | I-IV | NSCLC | CD3+/CD3+CD8+/CD4+CD25+ | OS | IHC | surgery |
| Fuqiang Dai[50] | 2010 | China | 99 | TN/TS | I-IV | NSCLC | CD8+ | OS | IHC | surgery |
| Feifei Teng[51] | 2016 | China | 126 | TS | I | NSCLC | CD8+/Foxp3+ | OS/DFS | IHC | surgery |
| Fayc¸al Djenidi[52] | 2015 | France | 101 | TN/TS | I | NSCLC | CD3+/CD8+/CD103 | OS/DFS | IHC | surgery |
| Enrico Ruffini[53] | 2009 | Italy | 1290 | TN | I-IIIA | NSCLC | TIL | OS | IHC | surgery |
| Eiki Kikuchi[19] | 2007 | Japan | 161 | TN/TS | I-IV | NSCLC | CD8+ | OS | IHC | surgery |
| Dermot S. O’Callaghan[20] | 2015 | Australia | 197 | TN/TS | I-IIIA | NSCLC | CD3+/CD8+/Foxp3+ | OS | IHC | surgery |
| Mariam Gachechiladze[54] | 2020 | Czech | 1205 | TN | I-III | NSCLC | CD3+/CD8+/TIL | OS/PFS | H&E | surgery |
| Fumihiko Kinoshita[55] | 2020 | Japan | 203 | TN | IA | NSCLC | CD8+/Foxp3+ | OS/DFS | IHC | surgery |
| Ahrong Kim[56] | 2019 | Korea | 146 | TN | I-IV | NSCLC | TIL | OS/PFS | H&E | surgery |
| Lu Chen[57] | 2019 | China | 354 | TN/TS | I-IV | NSCLC | CD8+ | OS | IHC | surgery |
| Yoshinori Handa[58] | 2020 | Japan | 126 | TN/TS | I | NSCLC | CD4+/CD8+/Foxp3+ | RFS | IHC | surgery |
| Arik Bernard Schulze[59] | 2020 | Germany | 294 | TN | I-III | NSCLC | CD4+/CD8+/Foxp3+ | OS/PFS | IHC | surgery |
| Kei Suzuki[60] | 2012 | USA | 478 | TS | I | NSCLC | Foxp3+ | RFS | IHC | surgery |
| Germán Corredor[12] | 2019 | USA | 301 | TN | I-II | NSCLC | TIL | RFS | H&E | surgery |
| Hee Eun Lee[61] | 2020 | USA | 120 | TN | I-IV | NSCLC | CD20+ | OS | IHC | surgery |
| Jianqing Hao[62] | 2020 | China | 192 | TN | I-IV | NSCLC | CD8+/Foxp3+ | OS | IHC | surgery |
| Senga K. Johnson[63] | 2000 | Scotland | 95 | TN | I-III | NSCLC | CD3+/CD8+/CD57+/CD68+ | OS | H&E/IHC | surgery |
| Katsuhiko Shimizu[64] | 2010 | Japan | 100 | TN | I-III | NSCLC | Foxp3+ | RFS | IHC | surgery |
TILs (tumour-infiltrating lymphocytes), TN (tumour nest), TS (tumour stroma), NSCLC (non-small cell lung cancer), FoxP3+ (factor forkhead box P3+), OS (overall survival), PFS (progression-free survival), DFS (disease-free survival), RFS (relapse/recurrence free survival), DSS (disease-specific survival), IHC (immunohistochemistry), H&E (haematoxylin and eosin).